Li Ren Kong

3.5k total citations
77 papers, 2.0k citations indexed

About

Li Ren Kong is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Li Ren Kong has authored 77 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 26 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in Li Ren Kong's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Esophageal Cancer Research and Treatment (7 papers). Li Ren Kong is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Esophageal Cancer Research and Treatment (7 papers). Li Ren Kong collaborates with scholars based in China, Singapore and United States. Li Ren Kong's co-authors include Liu C, Feifei Teng, Boon Cher Goh, Jinming Yu, Xiangjiao Meng, Yi Luan, Xiaohui Bai, Edward Lin, Andrea Li‐Ann Wong and Lingzhi Wang and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Li Ren Kong

72 papers receiving 2.0k citations

Peers

Li Ren Kong
Di Ge China
Jan Bouchal Czechia
So Dug Lim South Korea
Jeffrey Kiefer United States
Antje Habel Germany
Sara Bravaccini Italy
Jianxin Xue China
Xing Zhang China
Caigang Liu China
Di Ge China
Li Ren Kong
Citations per year, relative to Li Ren Kong Li Ren Kong (= 1×) peers Di Ge

Countries citing papers authored by Li Ren Kong

Since Specialization
Citations

This map shows the geographic impact of Li Ren Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Ren Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Ren Kong more than expected).

Fields of papers citing papers by Li Ren Kong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li Ren Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Ren Kong. The network helps show where Li Ren Kong may publish in the future.

Co-authorship network of co-authors of Li Ren Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Li Ren Kong. A scholar is included among the top collaborators of Li Ren Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li Ren Kong. Li Ren Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chong, Stephen Jun Fei, Junyan Lu, Rebecca Valentin, et al.. (2025). BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia. Molecular Cancer. 24(1). 62–62. 2 indexed citations
3.
Chen, Yue, Chi-Lin Tsai, Sarita Namjoshi, et al.. (2025). BRCA2 C-terminal clamp restructures RAD51 dimers to bind B-DNA for replication fork stability. Molecular Cell. 85(11). 2080–2096.e6. 3 indexed citations
4.
Chong, Wan Qin, Ross A. Soo, Hsiangling Teo, et al.. (2024). 848MO Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). Annals of Oncology. 35. S614–S614. 1 indexed citations
5.
Gray, G. Kenneth, Li Ren Kong, Komal Gupta, et al.. (2023). A transcriptional response to replication stress selectively expands a subset of Brca2-mutant mammary epithelial cells. Nature Communications. 14(1). 5206–5206. 3 indexed citations
6.
Wu, Bangyuan, Li Ren Kong, Chin Wen Png, et al.. (2021). DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death. Nature Communications. 12(1). 2284–2284. 48 indexed citations
7.
8.
Wang, Zhe, Minghuan Li, Feifei Teng, Li Ren Kong, & Jinming Yu. (2019). <p>Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma</p>. Cancer Management and Research. Volume 11. 2269–2280. 11 indexed citations
9.
Syn, Nicholas, Li Ren Kong, Lingzhi Wang, et al.. (2018). Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models. Signal Transduction and Targeted Therapy. 3(1). 9–9. 31 indexed citations
10.
Hirpara, Jayshree L., Jie Qing Eu, Andrea Li‐Ann Wong, et al.. (2018). Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance. Redox Biology. 25. 101076–101076. 91 indexed citations
11.
Wang, Lingzhi, Nicholas Syn, Vinod Vijay Subhash, et al.. (2018). Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. Cancer Letters. 417. 152–160. 69 indexed citations
12.
13.
Kong, Li Ren, et al.. (2017). P1.02-041 Characterization of MET-N375S as an Activating Mutation in Squamous Cell Carcinoma of the Lung. Journal of Thoracic Oncology. 12(1). S512–S512. 3 indexed citations
14.
Ong, Pei-Shi, Lingzhi Wang, Li Ren Kong, et al.. (2016). A novel combinatorial strategy using Seliciclib® and Belinostat® for eradication of non-small cell lung cancer via apoptosis induction and BID activation. Cancer Letters. 381(1). 49–57. 41 indexed citations
15.
Yu, Jinming, Feng Jin, Hui Zhu, Fang Shi, & Li Ren Kong. (2016). A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma. Clinical Interventions in Aging. 11. 167–167. 14 indexed citations
16.
Li, Minghuan, Xiaoli Zhang, Fen Zhao, et al.. (2016). Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. Radiation Oncology. 11(1). 18–18. 35 indexed citations
17.
Kong, Li Ren, Kian Ngiap Chua, Wen Jing Sim, et al.. (2015). MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 14(7). 1750–1760. 41 indexed citations
18.
Nissan, Moriah H., Christine A. Pratilas, Alexis M. Jones, et al.. (2014). Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. Cancer Research. 74(8). 2340–2350. 219 indexed citations
19.
20.
Zhang, Yingze, Li Ren Kong, Cathy S. Carlson, & Liu C. (2008). Cbfa1-dependent expression of an interferon-inducible p204 protein is required for chondrocyte differentiation. Cell Death and Differentiation. 15(11). 1760–1771. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Di Ge Breakdown of academic impact, for papers by Jan Bouchal Breakdown of academic impact, for papers by So Dug Lim Breakdown of academic impact, for papers by Jeffrey Kiefer Breakdown of academic impact, for papers by Antje Habel Breakdown of academic impact, for papers by Sara Bravaccini Breakdown of academic impact, for papers by Jianxin Xue Breakdown of academic impact, for papers by Xing Zhang Breakdown of academic impact, for papers by Caigang Liu
Rankless by CCL
2026